Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

By D. Kwekkeboom, J. Teunissen, W. Bakker, P. Kooij, W. D. de Herder, R. Feelders, C. van Eijck, J. Esser, B. Kam, E. Krenning. Journal of Clinical Oncology, 2005

648 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/e0f0e2ff4643cd9c1a479d2ef3d047b13076aead

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Kwekkeboom
2. W. D. de Herder
3. B. Kam
4. E. Krenning
5. C. van Eijck
6. M. van Essen
7. P. Kooij
8. R. Feelders

Citations in the corpus

• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. (2008, result): “Preliminary results in 131 patients with GEPNETs were also reported previously.(15) All patients gave written informed consent to participate in the study, which was approved by the hospital’s medical ethical committee.”
• Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011, neutral): “Diarrhea 49 (59) 45 (54) 4 (5) 32 (39) 30 (37) 2 (2)”